1. Anti-NXP2-Positive Paraneoplastic Dermatomyositis With Histopathologic Changes Confined to the Acrosyringia
- Author
-
Joaquín López-Robles, Hernán Quiceno, Maria del Carmen Vegas-Sánchez, Luis Requena, C. Bernárdez, Jose Luis Ramírez-Bellver, Elena Macías, and Jose Luis Diaz-Recuero
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Lung Neoplasms ,Paraneoplastic Syndromes ,Biopsy ,Dermatology ,Dermatomyositis ,Pathology and Forensic Medicine ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,X ray computed ,Adrenal Cortex Hormones ,Carcinoma, Non-Small-Cell Lung ,Carcinoma ,Medicine ,Neoplasm ,Humans ,Skin pathology ,Aged ,Autoantibodies ,Skin ,Adenosine Triphosphatases ,Immunoassay ,medicine.diagnostic_test ,business.industry ,Cancer ,General Medicine ,medicine.disease ,Primary tumor ,DNA-Binding Proteins ,stomatognathic diseases ,Treatment Outcome ,030228 respiratory system ,business ,Tomography, X-Ray Computed ,Biomarkers - Abstract
Paraneoplastic syndromes consist of a group of disorders that are not related to the extension of the primary tumor or its metastases and that might be the first manifestation of a hidden neoplasm. It is a well-known association between dermatomyositis (DM) and cancer, especially gynecological tumors in women and lung cancer in men.We describe the case of a 67-year-old male who developed muscular weakness and pruritic skin lesions. Skin biopsies were performed and histologic findings were consistent with DM.Skin biopsy showed interface dermatitis with vacuolar degeneration of the basal layer, dermal mucin deposits, and necrotic keratinocytes in the acrosyringia, a finding that has been previously reported in lupus erythematous but not in DM. Autoimmunity tests showed positivity for antinuclear antibodies and anti-NXP2, a recently described antibody associated with juvenile DM and, more rarely, with paraneoplastic DM.We present the first case in the literature with histopathologic changes of DM affecting the acrosyringia. Besides, our patient autoimmunity results support the utility of the new myositis-specific autoantibodies and its relation with a clinical phenotype.
- Published
- 2017